Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma
Authors:
- 20 May 2003
- journal article
- research article
- Published by Wiley in Clinical and Laboratory Haematology
- Vol. 25 (3) , 179-184
Abstract
High‐dose chemotherapy (HDC) with autologous peripheral blood stem cell (PBSC) support is a common but expensive treatment for various hematological malignancies. A prospective cost analysis of evaluation/mobilization and the HDC + PBSC phase for patients with multiple myeloma was performed. Eleven consecutive patients at the National University Hospital Oslo, taking part in a Nordic treatment protocol, were included in the analysis during the period from May 1999 to December 2000. Clinical and resource use data were obtained prospectively on a daily basis registration and from patient records.The total cost for the evaluation/mobilization and the HDC + PBSC phase varied from US$22 999 to US$61 722 (mean US$38 186; median US$30 569). The mean length of hospital stay for the evaluation/mobilization phase was 8 days (range 4–17 days) and for the HDC + PBSC phase 19 days (range 14–29 days). A statistically significant correlation was found between the length of hospital stay and hospital costs for both phases (P < 0.003 and P < 0.010, respectively). A large part of the actual cost in the harvest phase was attributed to stem cell mobilization, including growth factors, harvesting and cryopreservation. In the HDC + PBSC phase, the most important part of the cost was paying nursing care personnel.Keywords
This publication has 15 references indexed in Scilit:
- Low cost autologous peripheral blood stem cell transplantation performed in a municipal hospital for a patient with plasma cell leukaemiaClinical and Laboratory Haematology, 2002
- A prospective cost evaluation related to allogeneic haemopoietic stem cell transplantation including pretransplant procedures, transplantation and 1 year follow-up proceduresBone Marrow Transplantation, 2001
- Cost‐effectiveness of high‐dose chemotherapy in first‐line treatment of advanced multiple myelomaBritish Journal of Haematology, 2001
- Length of stay has minimal impact on the cost of hospital admission1Journal of the American College of Surgeons, 2000
- Cost analysis of the treatment of acute childhood lymphocytic leukaemia according to Nordic protocolsActa Paediatrica, 2000
- The development of a method for comparative costing of individual intensive care unitsAnaesthesia, 1999
- Comprehensive 1-year cost analysis of open antireflux surgery in Nordic countriesBritish Journal of Surgery, 1998
- G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costsBone Marrow Transplantation, 1998
- Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC)Bone Marrow Transplantation, 1997
- The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myelomaEuropean Journal of Cancer, 1994